Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally

This article was originally published in PharmAsia News

Executive Summary

Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.

You may also be interested in...



Novartis’ Serelaxin Poised For Standard FDA Review

Despite the fact that Novartis’ serelaxin has been granted breakthrough therapy designation from FDA, the heart failure candidate will receive a standard 12-month review, management said during a second quarter sales and earnings call.

The Name Game: Will Innovators’ Latest Battlefront Kill Biosimilars?

Having lost the battle to prevent biosimilars reaching the market at all, innovators are now pushing for them to be stamped with unique international non-proprietary names. That could prove commercially fatal for copycat biologics.

GPhA Battles State Biosimilar Bills; 5 Passed, 10 Rejected

Generic Pharmaceutical Association wants to assure legislation on biologics substitution does not impose more restrictions than required for small molecules; opposes measures pushed by Amgen and Genentech.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC084989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel